Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01019694 · ClinicalTrials.gov registry record · Phase 3
Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 470
- Enrollment target
NCT01019694 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 470 participants.
The verdict
NCT01019694, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 470 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate long-term safety and patient acceptability of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol Chlorofluorocarbon-Metered Dose Inhaler (CFC-MDI) and the free combination of ATROVENT Hydrofluoroalkane (HFA) and albuterol Hydrofluoroalkane (HFA) inhalation aerosols.
Interventions
- DRUG Combivent CFC-MDI
- DRUG Combivent Respimat 20/100 mcg
- DRUG Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01019694
The ClinicalTrials.gov registry entry for NCT01019694 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 470 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Combivent CFC-MDI is the first listed.
NCT01019694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01019694 about?
NCT01019694 is a clinical study titled "Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease". The primary objective of this study is to evaluate long-term safety and patient acceptability of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol Chlorofluorocarbon-Metered Dose Inhaler (CFC-MDI) and the free combination of ATROVENT Hydrofluoroalkane (HFA) and albu...
What is the current status of trial NCT01019694?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 470 participants. The study started on 2009-11.
What interventions are being tested in trial NCT01019694?
The interventions under investigation include: Combivent CFC-MDI (DRUG), Combivent Respimat 20/100 mcg (DRUG), Atrovent HFA 42 mcg + Albuterol HFA 200 mcg (DRUG).
Who is sponsoring clinical trial NCT01019694?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.